Alyeska Investment Group
RYTM icon

Alyeska Investment Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Alyeska Investment Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,589
Closed -$2.83M – 775
2026
Q1 		$2.83M Buy
+32,589
New +$3.17M 0.01% 529
2021
Q2 		– Sell
-73,957
Closed -$1.57M – 819
2021
Q1 		$1.57M Buy
+73,957
New +$2.14M 0.02% 508
2018
Q4 		– Sell
-8,590
Closed -$251K – 453
2018
Q3 		$251K Sell
8,590
-98,517
-92% -$3.11M ﹤0.01% 390
2018
Q2 		$3.35M Buy
+107,107
New +$2.93M 0.03% 308

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Alyeska Investment Group's RYTM Position: Q2 2026 in Review

Alyeska Investment Group sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 32,589 shares — an estimated $2.83M sold.

Alyeska Investment Group first reported a position in RYTM in Q2 2018 and held it in 4 quarters. The position peaked at $3.35M in Q2 2018. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Alyeska Investment Group reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 32,589 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $2.83M.
  • Alyeska Investment Group first reported a position in Rhythm Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Alyeska Investment Group's Rhythm Pharmaceuticals position peaked at $3.35M in Q2 2018.
  • 302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.